Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ticarcillin Disodium

FDA-approved product (injectable, injection), marketed as Ticar.

Registered studies
11
Lab records
63
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Ticarcillin Disodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Penicillins with extended spectrum
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CA13

Repurposing investigation

Ticarcillin Disodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA72.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli18.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae7.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis34.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

11registered studies name this medicine, for any condition. See them below.

Experimental

  • K. pneumoniae: measured active in 0 of 63 lab records
Open Ticarcillin Disodium in ChEMBL Registered studies below
Show the 63 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

Docking did not produce a scoredetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ticarcillin Disodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Combination Antibiotic Therapy Compared to Monotherapy in the Treatment of Acute COPD

    NCT04879030 · start 2020-01-01

    Registered record
    Registry ID
    NCT04879030
    Conditions
    COPD Exacerbation Acute
    Interventions
    Beta-Lactams; Fluoroquinolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2020-01-01
    Completion
    2020-12-30
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOPD Exacerbation Acute
    InterventionBeta-Lactams; Fluoroquinolone
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial

    NCT02800785 · start 2016-05

    Registered record
    Registry ID
    NCT02800785
    Conditions
    Appendicitis
    Interventions
    Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin; Appendectomy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-05
    Completion
    2021-09-01
    Enrolment
    1,552

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAppendicitis
    InterventionCefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin; Appendectomy
    PhaseNot applicable
    Registry statusCompleted

  • Patients Response to Early Switch To Oral:Osteomyelitis Study

    NCT02099240 · start 2014-03-06

    Registered record
    Registry ID
    NCT02099240
    Conditions
    Osteomyelitis
    Interventions
    oral antibiotics; intravenous antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2014-03-06
    Completion
    2018-11-07
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis
    Interventionoral antibiotics; intravenous antibiotics
    PhaseEarly phase 1
    Registry statusTerminated

  • Technology That Permits Focal Dose of Antibiotics to be Delivered to Lower Limb(s) of Diabetic Patients

    NCT02158442 · start 2013-10

    Registered record
    Registry ID
    NCT02158442
    Conditions
    Diabetes; Infection
    Interventions
    Percutaneous Isolated Limb Perfusion (PILP) delivery; Timentin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-10
    Completion
    2015-03
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; Infection
    InterventionPercutaneous Isolated Limb Perfusion (PILP) delivery; Timentin
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetics (PK) of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio)

    NCT01728363 · start 2013-01

    Registered record
    Registry ID
    NCT01728363
    Conditions
    Systemic Infection
    Interventions
    Antibiotic
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-01
    Completion
    2015-05
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystemic Infection
    InterventionAntibiotic
    PhasePhase 1
    Registry statusCompleted

  • A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis

    NCT01667094 · start 2012-09

    Registered record
    Registry ID
    NCT01667094
    Conditions
    Cystic Fibrosis
    Interventions
    Intermittent, short infusion Ceftazidime; Continuous infusion Ceftazidime; Intermittent, short infusion Meropenem; Continuous infusion Meropenem; Intermittent, short infusion Ticarcillin-clavulanate; Continuous infusion Ticarcillin-clavulanate; Intermittent, short infusion Cefepime; Continuous infusion Cefepime; Continuous infusion Piperacillin tazobactam; Intermittent, short infusion Piperacillin tazobactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2012-09
    Completion
    2017-07
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionIntermittent, short infusion Ceftazidime; Continuous infusion Ceftazidime; Intermittent, short infusion Meropenem; Continuous infusion Meropenem +6 more
    PhasePhase 4
    Registry statusUnknown

  • WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics

    NCT01587768 · start 2011-11

    Registered record
    Registry ID
    NCT01587768
    Conditions
    Infections, Bacterial
    Interventions
    Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-11
    Completion
    2014-07
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections, Bacterial
    InterventionAntibiotic prescription during the study period between January 1, 2004 and December 31, 2009
    PhaseNot recorded
    Registry statusCompleted

  • Pharmacokinetics and Safety of Ticarcillin-clavulanate in Infants

    NCT01229046 · start 2010-09

    Registered record
    Registry ID
    NCT01229046
    Conditions
    Sepsis
    Interventions
    Ticarcillin-clavulanic acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2010-09
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis
    InterventionTicarcillin-clavulanic acid
    PhasePhase 1
    Registry statusWithdrawn

  • Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

    NCT00153634 · start 2004-03

    Registered record
    Registry ID
    NCT00153634
    Conditions
    Cystic Fibrosis; Chronic Bronchitis
    Interventions
    IV amikacin; PO azithromycin; IV ceftazidime; PO ciprofloxacin; IV meropenem; IV piperacillin-tazobactam; IV ticarcillin-clavulanate; IV tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2004-03
    Completion
    2007-11
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis; Chronic Bronchitis
    InterventionIV amikacin; PO azithromycin; IV ceftazidime; PO ciprofloxacin +4 more
    PhaseNot applicable
    Registry statusCompleted

  • An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038)

    NCT00092170 · start 2002-03

    Registered record
    Registry ID
    NCT00092170
    Conditions
    Infections; Pelvic Infections
    Interventions
    MK0826, ertapenem sodium; Comparator: Ticarcillin/Clavulanate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-03
    Completion
    2004-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections; Pelvic Infections
    InterventionMK0826, ertapenem sodium; Comparator: Ticarcillin/Clavulanate
    PhasePhase 2
    Registry statusCompleted

  • A Study of the Safety and Effectiveness of Levofloxacin Compared to Ticarcillin/Clavulanate Alone or Followed by Amoxicillin/Clavulanate in the Treatment of Complicated Skin Infections

    NCT00249197 · start 1997-01

    Registered record
    Registry ID
    NCT00249197
    Conditions
    Skin Diseases, Bacterial
    Interventions
    levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1997-01
    Completion
    1998-07
    Enrolment
    413

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Diseases, Bacterial
    Interventionlevofloxacin
    PhasePhase 3
    Registry statusCompleted